Abstract

BackgroundReducing rescue medication use is a guideline-defined goal of asthma treatment, however, little is known about the validity of rescue medicine use as a marker of symptoms in chronic obstructive pulmonary disease (COPD). To improve patient outcomes, greater insight is needed into the relationship between rescue medication use and alternative COPD outcomes.MethodsA systematic search of electronic databases (Embase®, MEDLINE® and Cochrane CENTRAL) was conducted from database start to 26 May, 2015. Studies of bronchodilator therapy with a duration of ≥24 weeks were included if they reported either mean change from baseline (CFB) in rescue medication use in puffs/day or % rescue-free days (%RFD), and at least one other COPD endpoint. Correlation and meta-regression analyses were undertaken to test the association between rescue medication use and other COPD outcomes using weighted means (weights proportional to the sample size of the treatment group) and unweighted means (equal weight for each treatment group). Each association was assessed at 6 months and study end.ResultsForty-six studies involving 46,531 patients provided mean data from 145 treatment groups for evaluation. Changes in both measures of rescue medication use were correlated with changes in trough forced expiratory volume in one second ([FEV1]; Pearson correlation coefficients |r| ≥ 0.63; p < 0.0001) and with St George’s Respiratory Questionnaire (SGRQ) score (|r| ≥ 0.70; p < 0.0001) at study end. Change in rescue medication use in puffs/day during the study correlated with annualized rates of moderate/severe exacerbations at 6 months and study end (both r = 0.66; p ≤ 0.0028). CFB in puffs/day was not well correlated with Transition Dyspnoea Index (TDI), but %RFD did correlate with TDI score at 6 months and study end (both r = 0.69; p < 0.0001). The values for CFB in puffs/day corresponding to the proposed minimal clinically important differences for trough FEV1 and SGRQ score were -1.3 and -0.6 puffs/day, respectively. A -1.0 puffs/day CFB in rescue use corresponded to a change of 0.26 events/patient-year in moderate/severe exacerbations.ConclusionThis analysis provides clear evidence of associations at a patient group level between rescue medication use and other clinically important COPD outcomes.

Highlights

  • Reducing rescue medication use is a guideline-defined goal of asthma treatment, little is known about the validity of rescue medicine use as a marker of symptoms in chronic obstructive pulmonary disease (COPD)

  • Spirometry assessments are important for the characterization and management of COPD, but the Global initiative for chronic Obstructive Lung Disease (GOLD) guidelines recommend that the symptoms experienced by each individual patient and their exacerbation history should be considered [2]

  • The distribution of study treatment groups and patients across treatment categories is provided in Table 1, with most patients receiving Long-acting β2-agonist (LABA) (34.5%), LABA + inhaled corticosteroid (ICS) (20.0%) or Long-acting muscarinic antagonist (LAMA) (18.5%)

Read more

Summary

Introduction

Reducing rescue medication use is a guideline-defined goal of asthma treatment, little is known about the validity of rescue medicine use as a marker of symptoms in chronic obstructive pulmonary disease (COPD). Spirometry assessments are important for the characterization and management of COPD, but the Global initiative for chronic Obstructive Lung Disease (GOLD) guidelines recommend that the symptoms experienced by each individual patient and their exacerbation history should be considered [2]. Rescue medication use is commonly measured in clinical trials of patients with asthma and COPD. To the best of our knowledge, no previous systematic reviews have assessed the association between increased rescue medication use and other clinical trial outcomes such as changes in trough

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call